Abstract
BackgroundMonocyte chemoattractant protein −1 (MCP-1) plays an important role in the development of diseases related to metabolic syndromes, such as type 2 diabetes mellitus (T2DM) and its complications. The present study investigates the relationship between the methylation status of CpG sites in the MCP-1 promoter and T2DM and its complications in Morocco. Material and methodsWe conducted a population-based case-control study of 108 T2DM cases and 101 controls. Methylation Specific Polymerase chain reaction (MSP) was used to analyze the MCP-1 methylation profile in leucocyte's DNA. ResultsThis study did not indicate a significant association between the methylation status of CpG sites in the MCP1 promoter and T2DM and its complications (p ˃ 0.05). The hypomethylation profile is significantly associated with higher LDL-C levels (142.37 ± 58.37; p = 0.041) and treatment with antidepressants (18.8%; p = 0.043) in patients with T2DM. The hypermethylation profile is most frequently observed in type 2 diabetic patients with complications and cigarettes smokers (31.6%; p = 0.052). ConclusionResults of our study showed no association between the methylation status of CpG in the MCP-1 promoter and T2DM and its complications in the Moroccan population. However, the methylation status might be related to LDL-C levels, treatment with antidepressants, and smoking status.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
